CN109310669B - 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 - Google Patents

氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 Download PDF

Info

Publication number
CN109310669B
CN109310669B CN201780030912.5A CN201780030912A CN109310669B CN 109310669 B CN109310669 B CN 109310669B CN 201780030912 A CN201780030912 A CN 201780030912A CN 109310669 B CN109310669 B CN 109310669B
Authority
CN
China
Prior art keywords
trigeminal
trigeminal neuralgia
use according
painful
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780030912.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109310669A (zh
Inventor
曹民宰
黄善宽
李翰柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN109310669A publication Critical patent/CN109310669A/zh
Application granted granted Critical
Publication of CN109310669B publication Critical patent/CN109310669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780030912.5A 2016-05-19 2017-05-18 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 Active CN109310669B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0061386 2016-05-19
KR20160061386 2016-05-19
PCT/KR2017/005172 WO2017200317A1 (ko) 2016-05-19 2017-05-18 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
CN109310669A CN109310669A (zh) 2019-02-05
CN109310669B true CN109310669B (zh) 2022-02-22

Family

ID=60325324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780030912.5A Active CN109310669B (zh) 2016-05-19 2017-05-18 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途

Country Status (14)

Country Link
US (2) US11207295B2 (enExample)
EP (1) EP3459542B1 (enExample)
JP (1) JP6960415B2 (enExample)
KR (1) KR102421013B1 (enExample)
CN (1) CN109310669B (enExample)
AU (1) AU2017267160B2 (enExample)
CA (1) CA3024284C (enExample)
DK (1) DK3459542T3 (enExample)
ES (1) ES2887338T3 (enExample)
MX (1) MX389613B (enExample)
PL (1) PL3459542T3 (enExample)
PT (1) PT3459542T (enExample)
RU (1) RU2751504C2 (enExample)
WO (1) WO2017200317A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228138A (zh) * 2005-04-22 2008-07-23 Sk株式会社 神经治疗吡咯化合物
CN102574821A (zh) * 2009-10-15 2012-07-11 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法
CN102803233A (zh) * 2009-06-22 2012-11-28 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
EP0959882A4 (en) * 1996-12-31 2001-12-05 N-BONDED UREAUTIES AND CARBAMATES OF HETEROCYCLIC THIOESTERS
MXPA03007721A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuesto de carbamato para su uso en el tratamiento del dolor.
JP4227121B2 (ja) * 2005-06-08 2009-02-18 独立行政法人科学技術振興機構 神経因性疼痛治療剤
KR20140009244A (ko) * 2010-11-11 2014-01-22 애크런 몰레큘스 게엠베하 통증 치료용 화합물 및 방법
SI3054950T1 (sl) * 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228138A (zh) * 2005-04-22 2008-07-23 Sk株式会社 神经治疗吡咯化合物
CN102803233A (zh) * 2009-06-22 2012-11-28 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法
CN102574821A (zh) * 2009-10-15 2012-07-11 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development;Gaetano Zaccara等;《Pharmacological Research》;20151212;第104卷;第38-48页 *
Meir Bialer等.Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X).《Epilepsy Research》.2010,第92卷第89-124页. *
Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X);Meir Bialer等;《Epilepsy Research》;20101201;第92卷;第89-124页 *
加巴喷丁与卡马西平治疗三叉神经痛的对比分析;陈忠红;《中国卫生标准管理》;20150721;第15卷;第133-134页 *

Also Published As

Publication number Publication date
BR112018073556A2 (pt) 2019-03-19
MX2018014081A (es) 2019-09-02
AU2017267160A1 (en) 2018-12-13
CN109310669A (zh) 2019-02-05
EP3459542A4 (en) 2020-01-08
US12611395B2 (en) 2026-04-28
KR20170131241A (ko) 2017-11-29
ES2887338T3 (es) 2021-12-22
RU2018144784A (ru) 2020-06-19
CA3024284A1 (en) 2017-11-23
EP3459542B1 (en) 2021-06-30
US20190175555A1 (en) 2019-06-13
RU2018144784A3 (enExample) 2020-08-11
JP2019516722A (ja) 2019-06-20
US11207295B2 (en) 2021-12-28
KR102421013B1 (ko) 2022-07-14
US20220087976A1 (en) 2022-03-24
DK3459542T3 (da) 2021-09-13
EP3459542A1 (en) 2019-03-27
PL3459542T3 (pl) 2021-12-27
MX389613B (es) 2025-03-20
CA3024284C (en) 2024-01-23
RU2751504C2 (ru) 2021-07-14
AU2017267160B2 (en) 2022-11-10
PT3459542T (pt) 2021-08-24
WO2017200317A1 (ko) 2017-11-23
JP6960415B2 (ja) 2021-11-05

Similar Documents

Publication Publication Date Title
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
ES2743153T3 (es) Métodos para tratar el síndrome de fibromialgia
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
US12611395B2 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
ES2813649T3 (es) Composición farmacéutica administrable por vía oral para la prevención o el tratamiento del síndrome del ojo seco, que comprende rebamipida o un profármaco de la misma
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
EP3711757B1 (en) Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
HK40003859A (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
HK40003859B (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
BR112018073556B1 (pt) Uso de um composto de carbamato
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003859

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant